Anadkat MJ - Search Results

1

Dermatologic adverse events to chemotherapeutic agents, part 1: cytotoxics, epidermal growth factor receptors, multikinase inhibitors, and proteasome inhibitors.

Kyllo RL, Anadkat MJ. Kyllo RL, et al. Among authors: anadkat mj. Semin Cutan Med Surg. 2014 Mar;33(1):28-39. doi: 10.12788/j.sder.0060. Semin Cutan Med Surg. 2014. PMID: 25037256 Review.

2

The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) score: online assessment and validation study of a specific measure of GPP disease activity.

Burden AD, Bachelez H, Choon SE, Marrakchi S, Tsai TF, Turki H, Morita A, Lebwohl MG, Bissonnette R, Zheng M, Anadkat MJ, Navarini AA, Tang M, Thoma C, Duffin KC. Burden AD, et al. Among authors: anadkat mj. Br J Dermatol. 2023 Jul 7;189(1):138-140. doi: 10.1093/bjd/ljad071. Br J Dermatol. 2023. PMID: 37075220 Free article. No abstract available.

3

Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.

Wu PA, Balagula Y, Lacouture ME, Anadkat MJ. Wu PA, et al. Among authors: anadkat mj. Curr Opin Oncol. 2011 Jul;23(4):343-51. doi: 10.1097/CCO.0b013e3283474063. Curr Opin Oncol. 2011. PMID: 21537180 Review.

4

Dermatologic manifestations of cytotoxic therapy.

Huang V, Anadkat M. Huang V, et al. Dermatol Ther. 2011 Jul-Aug;24(4):401-10. doi: 10.1111/j.1529-8019.2011.01432.x. Dermatol Ther. 2011. PMID: 21910798 Review.

5

Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors.

Brodell LA, Hepper D, Lind A, Gru AA, Anadkat MJ. Brodell LA, et al. Among authors: anadkat mj. J Cutan Pathol. 2013 Oct;40(10):865-70. doi: 10.1111/cup.12202. Epub 2013 Aug 14. J Cutan Pathol. 2013. PMID: 23941617 Clinical Trial.

6

EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections.

Braden RL, Anadkat MJ. Braden RL, et al. Among authors: anadkat mj. Support Care Cancer. 2016 Sep;24(9):3943-50. doi: 10.1007/s00520-016-3231-1. Epub 2016 Apr 27. Support Care Cancer. 2016. PMID: 27117557

7

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS. Romee R, et al. Among authors: anadkat mj. Blood. 2018 Jun 7;131(23):2515-2527. doi: 10.1182/blood-2017-12-823757. Epub 2018 Feb 20. Blood. 2018. PMID: 29463563 Free PMC article. Clinical Trial.

8

Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole.

Wanat KA, Anadkat MJ, Klekotka PA. Wanat KA, et al. Among authors: anadkat mj. J Am Acad Dermatol. 2009 Apr;60(4):589-94. doi: 10.1016/j.jaad.2008.11.884. Epub 2009 Feb 13. J Am Acad Dermatol. 2009. PMID: 19217690

9

Tufted hair folliculitis in a woman treated with trastuzumab.

Rosman IS, Anadkat MJ. Rosman IS, et al. Among authors: anadkat mj. Target Oncol. 2010 Dec;5(4):295-6. doi: 10.1007/s11523-010-0162-5. Epub 2010 Oct 15. Target Oncol. 2010. PMID: 20949375

10

Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.

Huang V, Hepper D, Anadkat M, Cornelius L. Huang V, et al. Arch Dermatol. 2012 May;148(5):628-33. doi: 10.1001/archdermatol.2012.125. Arch Dermatol. 2012. PMID: 22431713

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

81 results

Search Page

Filters